Lifecare is revolutionising the daily lives of millions of diabetics who need to check their blood sugar levels several times a day. This is typically done by a blood test. Lifecare has developed a very small sensor (see the video for how small) that inserted under the skin continuously monitors blood glucose levels. The product is on its way to regulatory approval – watch the video with CEO Joacim Holter about the process leading up to launch.
Lifecare is a medtech company listed on Euronext Growth Oslo with the ticker LIFE. Lifecare is developing a revolutionary, miniature biosensor with pressure sensor produced in nanoscale that can continuously monitor the glucose (sugar) level in the blood when inserted in the wrist, for example. This is urgently needed by the more than 500 million patients with diabetes, but currently the most commonly used method is multiple daily blood sampling. Lifecare’s sensor can also be used to detect other biomacurs, but currently the company’s focus is diabetes and to launch Sencell Glucose in 2024.
Read more: Lifecare faces a decisive month
